title: [Immunotherapies and targeted therapies in medical oncology].
abstract: New immunotherapies, also called "immune checkpoints", are promising and showed interesting antitumoral activities in particular in advanced setting of melanoma, clear cell renal cancer or non-small cell lung carcinoma. These treatments include ipilimumab, anti-PD-1 and anti-PD-L1. There is a strong rational for combination of immunotherapies and targeted therapies. This review is dedicated to expose the theorical issues and preclinical data of such combinations. This review examined the impact of immunotherapies on transduction pathways and modification of immunity related to targeted therapies. First clinical data form early drug development studies showed the difficulties observed with such combination and limitating toxicities. Finally, potential interesting combinations are overviewed with an emphasis on sequential treatments.
authors: Gustave-Roussy, université Paris-Sud, DITEP, département des innovations thérapeutiques et des essais précoces, 114, rue Édouard-Vaillant, 94800 Villejuif, France.
authors: Benoît
authors: B
authors: Rousseau
authors: Gustave-Roussy, université Paris-Sud, DITEP, département des innovations thérapeutiques et des essais précoces, 114, rue Édouard-Vaillant, 94800 Villejuif, France.
authors: Stéphane
authors: S
authors: Champiat
authors: Gustave-Roussy, université Paris-Sud, DITEP, département des innovations thérapeutiques et des essais précoces, 114, rue Édouard-Vaillant, 94800 Villejuif, France.
authors: Delphine
authors: D
authors: Loirat
authors: Gustave-Roussy, université Paris-Sud, DITEP, département des innovations thérapeutiques et des essais précoces, 114, rue Édouard-Vaillant, 94800 Villejuif, France.
authors: Jennifer
authors: J
authors: Arrondeau
authors: Gustave-Roussy, université Paris-Sud, DITEP, département des innovations thérapeutiques et des essais précoces, 114, rue Édouard-Vaillant, 94800 Villejuif, France.
authors: Nathalie
authors: N
authors: Lemoine
authors: Gustave-Roussy, université Paris-Sud, DITEP, département des innovations thérapeutiques et des essais précoces, 114, rue Édouard-Vaillant, 94800 Villejuif, France.
authors: Jean-Charles
authors: JC
authors: Soria
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D060890:B7-H1 Antigen / Q000037:antagonists & inhibitors*; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology / Q000628:therapy; D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000628:therapy; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy / Q000379:methods; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D000074324:Ipilimumab; D007680:Kidney Neoplasms / Q000276:immunology / Q000628:therapy; D008175:Lung Neoplasms / Q000276:immunology / Q000628:therapy; D008545:Melanoma / Q000276:immunology / Q000628:therapy; D058990:Molecular Targeted Therapy / Q000379:methods*; D019869:Phosphatidylinositol 3-Kinases / Q000276:immunology; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors; D051057:Proto-Oncogene Proteins c-akt / Q000276:immunology; D015398:Signal Transduction; D058570:TOR Serine-Threonine Kinases / Q000276:immunology
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D060890:B7-H1 Antigen; D000074324:Ipilimumab; D019869:Phosphatidylinositol 3-Kinases; D061026:Programmed Cell Death 1 Receptor; D048493:Proto-Oncogene Proteins B-raf; D051057:Proto-Oncogene Proteins c-akt; D058570:TOR Serine-Threonine Kinases; C423236:CD274 protein, human; C105992:PDCD1 protein, human; C546842:MTOR protein, human; C482119:BRAF protein, human
keywords: clinical trial/phase I; drug therapy/combination; immunotherapy; molecular targeted therapy